Quantcast

Latest Rosetta Genomics Stories

2010-06-10 07:30:00

FREMONT, Calif., June 10 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability. By querying up to a thousand genes in a single sample, these panels enable discovery and validation of biomarkers in a high-throughput, highly...

2010-03-16 07:30:00

FREMONT, Calif., March 16 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced that Ghent University (UGent) in Belgium has signed a research collaboration and is an early-access customer for the WaferGen SmartChip(TM) Real-Time PCR System. Under the terms of the collaboration, UGent will be part of WaferGen's early-access SmartChip program with shipment occurring in the first...

2009-12-16 15:29:00

FREMONT, Calif., Dec. 16 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced that it will be launching the Human MicroRNA Panel for its innovative service for gene-expression profiling using its SmartChip(TM) Real-Time PCR System. The Human MicroRNA Panel provides the most comprehensive human microRNA panel of 885 microRNAs on a single SmartChip. The company's SmartChip service...

2009-12-09 10:00:00

CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states,...

2009-10-15 06:00:00

SAN DIEGO, Oct. 15 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology. "Prometheus has a long and successful history of providing innovative diagnostics that complement targeted therapeutics to...

2009-08-25 12:50:06

Researchers continue to add to the diagnostic alphabet of saliva by identifying the presence of at least 50 microRNAs that could aid in the detection of oral cancer, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research."It is a Holy Grail of cancer detection to be able to measure the presence of a cancer without a biopsy, so it is very appealing to think that we could detect a cancer-specific marker in a patient's saliva," said Jennifer...

2009-06-01 06:00:00

New Product Names for Recently Introduced MicroRNA-based Diagnostics Also Unveiled SAN DIEGO, June 1 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, presented an overview of its proprietary oncology diagnostic platform yesterday at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando. In a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) Activation in Circulating Tumor Cells (CTCs) in Metastatic Tumors...

2009-05-04 07:00:00

From Bench to Bedside MOUNTAIN VIEW, Calif., May 4 /PRNewswire/ -- Despite growing competition from new entrants, microRNA tool providers are witnessing extraordinary growth in their research product portfolios. As evidence of the link between microRNAs and disease grows, the diagnostic and therapeutic potential of these molecules will remain the driving forces behind market expansion. MicroRNA research offers the capability of moving from bench to bedside faster than most research fields,...

2009-04-13 06:00:00

MicroRNA-based Molecular Diagnostics to Mark Prometheus' Entry into Oncology Market; Rosetta to Receive Milestones and Research and Development Funding plus Future Royalties SAN DIEGO, PHILADELPHIA and REHOVOT, Israel, April 13 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of a license and collaboration agreement under which...

2009-03-19 13:51:41

New York researchers identified genetic markers that signal poor outcomes for patients with head and neck cancer. The findings, published in the American Journal of Pathology, could one day lead to a genetic test that could help select or predict successful treatment options for patients with tumors in the mouth, throat or larynx. Surgery, chemotherapy and radiation are the main treatment options but cause serious side effects that can affect quality of life. Scientists at Albert Einstein...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related